Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05460052
Other study ID # 69HCL21_1430
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 26, 2022
Est. completion date November 24, 2023

Study information

Verified date January 2024
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder resulting from the selective loss of hypocretin neurons. Patients with NT1 suffer from excessive daytime sleepiness, disrupted nighttime sleep, and cataplexy (emotionally triggered episodes of muscle atonia). The disease is associated with numerous comorbidities such as obesity, metabolic disorders, anxiety-depressive disorders, and attentional disorders, all of which have a strong impact on quality of life.


Description:

Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder resulting from the selective loss of hypocretin neurons. Patients with NT1 suffer from excessive daytime sleepiness, disrupted nighttime sleep, and cataplexy (emotionally triggered episodes of muscle atonia). The disease is associated with numerous comorbidities such as obesity, metabolic disorders, anxiety-depressive disorders, and attentional disorders, all of which have a strong impact on quality of life. Current management is based on sleep hygiene as well as wake-promoting and anti-cataplectic medications. However, many patients complain of residual sleepiness or cataplexy. In addition, most of the proposed treatments are accompanied by side effects and have little effect on the comorbidities associated with the disease. Therapeutic alternatives are therefore needed in the management of narcolepsy. Regular Physical Activity (RPA) is recommended by the World Health Organization (WHO) and has been shown to improve anxiety disorders, obesity, metabolic disorders, cognitive functions, sleep and quality of life. In NT1, patients have fewer opportunities to practice RPA because of daytime sleepiness as well as increased sleep needs. Some studies suggest that cardiorespiratory performances may be lower in NT1 patients than in healthy controls, and that a higher level of physical activity may be associated with lower sleepiness and better metabolic profile in NT1 children. However, no prospective study has evaluated the feasibility of an exercise training program in NT1 or the effect of regular physical activity on disease severity. The main objective of the study is to evaluate the effect of a physical activity training program of 3 sessions per week for 6 weeks on the severity of narcolepsy in sedentary adults with NT1. The secondary objectives are to evaluate the feasibility of this program in an adult NT1 population, the effect of the program on comorbidities (obesity, metabolic disorders, anxiety-depressive symptoms, cognitive disorders), medication dosage and quality of life, its tolerance, and the satisfaction of the patients at short- (6 weeks) and long-term (6 months).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 24, 2023
Est. primary completion date November 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosis of Narcolepsy type 1 according to International Classification of Sleep Disorders, 3rd edition (ICSD 3-2014) criteria - Patients aged 18 to 65 years - Patients beneficiaries of social security - Signed consent to participate in the study - Access to a video conferencing device (smartphone, tablet or computer) Exclusion Criteria: - - Patients with a high level of physical activity on the Ricci and Gagnon Questionnaire (score >35) and/or regular physical activity in clubs - Treatments not stabilized for less than 3 months - Cognitive disorders incompatible with the understanding and implementation of the program - Medical contraindication to exercise training - Patient working night shifts - Unstable somatic or psychiatric pathology - Severe untreated obstructive sleep apnea syndrome (apnea/hypopnea index >30/h) - Pregnancy in progress or breastfeeding - Persons deprived of liberty by a judicial or administrative decision, - Persons admitted to a health or social institution for purposes other than research - Persons of full age who are subject to a legal protection measure or who are unable to express their consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physical activity training program
The physical activity training program will consist of 3 sessions per week for 6 weeks : 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference.
Weekly phone call.
Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.
Personalized training plan.
After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.

Locations

Country Name City State
France Service de médecine du sommeil et des maladies respiratoires Lyon

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline Narcolepsy Severity Scale (NSS) Score after training period. The Narcolepsy Severity Scale is a validated scale exploring the different symptoms of NT1 before and after 6 weeks of physical activity program (training period)
Secondary Narcolepsy Severity Scale (NSS) Score The Narcolepsy Severity Scale is a validated scale exploring the different symptoms of NT1 At 6 months
Secondary Compliance with the training program. It will be expressed as the percentage of sessions completed weekly during the training period (up to 6 weeks)
Secondary Hospital and Anxiety Depression Scale score At inclusion, at the end of the training program (6 weeks) and at 6 months
Secondary Frequency of cataplexy Items 8and 9 of the NSS are used to assess frequency of cataplexy every week during de training period (6 weeks)
Secondary Bron/Lyon Attention Stability Test (BLAST) score Parameters will be measured at inclusion, at the end of the training program (6 weeks)
Secondary body mass index Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months*
Secondary Maximal Oxygen consumption (VO2 max) Parameters will be measured at inclusion, at the end of the training program (6 weeks)
Secondary Fasting blood sugar Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months*
Secondary Lipid profile Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months*
Secondary patient satisfaction score Parameters will be measured at inclusion, at the end of the training program (6 weeks)
Secondary sleep efficiency Sleep efficiency is defined as the ratio between total sleeping time and time spent in bed Parameters will be measured at inclusion, at the end of the training program (6 weeks) and at 6 months*
Secondary Euroquol 5 dimensions questionnaire score At inclusion, at the end of the training program (6 weeks) and at 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05983731 - A Pilot Observational Study to Assess the Ability of Continuous 'Home' EEG to Accurately Diagnose Narcolepsy and Demonstrate Response to Treatment
Suspended NCT04419792 - 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
Completed NCT05375890 - Clinical and Neurophysiological Characteristics of Narcolepsy
Not yet recruiting NCT06292598 - Bacterial Translocation and Gut Microbiota in Type 1 Narcolepsy Patients Versus a Control Population
Recruiting NCT06358950 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) Phase 2
Not yet recruiting NCT06457945 - Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions N/A
Not yet recruiting NCT06383806 - Decreasing Nightmares in Adults With Narcolepsy N/A
Not yet recruiting NCT05914194 - A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1 Phase 3
Completed NCT05687903 - A Study of TAK-861 in Participants With Narcolepsy Type 1 Phase 2
Recruiting NCT05967832 - Contribution of 7 Tesla MRI of the Hypothalamus in the Diagnosis of Type 1 Narcolepsy N/A
Completed NCT05709873 - Narcolepsy Nightmare Study N/A
Recruiting NCT04483310 - Meditation-Relaxation (MR Therapy) for Sleep Paralysis. N/A
Completed NCT04445129 - Wake and Sleep State Transitions on a Portable Electroencephalogram (EEG) Device in Narcolepsy Type 1 (NT1) and Healthy Participants
Completed NCT05314556 - Group Psychotherapy in Narcolepsy Type 1 N/A
Recruiting NCT05816382 - A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions Phase 2/Phase 3
Recruiting NCT06336057 - Mentalizating in Adults Suffering From Narcolepsy Type 1.
Recruiting NCT06251063 - Improving Social Relationships for Adolescents With Central Disorders of Hypersomnolence N/A
Completed NCT06241911 - Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1 N/A